OS Therapies is a clinical-stage biopharmaceutical company incorporated in Delaware and headquartered in Grasonville, Maryland. The company focuses on identifying, developing, and commercializing treatments for osteosarcoma and other solid tumors. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy candidate for osteosarcoma patients, and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate utilizing a proprietary silicone dioxide linker technology platform designed with tunable pH-sensitive characteristics.
The company's technology platform centers on a plug-and-play approach to antibody-drug conjugate development, featuring customizable silicone linkers that can be adjusted for different therapeutic applications. This platform aims to address challenges in targeted oncology treatment.
OS Therapies operates as a private development-stage enterprise with a small team of four full-time employees. The company is listed on the NYSE and incorporated in Delaware. As a clinical-stage entity, the organization has not generated meaningful commercial revenue and remains focused on advancing its pipeline candidates through development stages.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.88 | $-0.88 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-31 | 0001213900-25-026238 | SEC ↗ |